OncoMatch/Clinical Trials/NCT07063745
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Is NCT07063745 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments for metastatic non-small cell lung cancer with mtap deletion.
Treatment: BMS-986504 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed · Paclitaxel · Nab-paclitaxel — The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MTAP homozygous deletion
homozygous methylthioadenosine phosphorylase (MTAP) deletion
Required: MTAP loss
MTAP loss
Disease stage
Required: Stage IV (American Joint Committee on Cancer, Ninth Edition)
Metastatic disease required
Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy)
Exception: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated.
Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology and Hematology · Anchorage, Alaska
- Mayo Clinic in Arizona - Phoenix · Phoenix, Arizona
- Local Institution - 0120 · Tucson, Arizona
- Highlands Oncology Group · Springdale, Arkansas
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07063745 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MTAP?
Yes, MTAP homozygous deletion is a required biomarker for enrollment.
Does this trial require MTAP?
Yes, MTAP loss is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages